Background Cisplatin (CDDP) is one of the most important chemotherapeutic agents in the treatment of advanced gastric cancer, but its efficacy is limited by CDDP resistance. Because the transcription factor FOXO1 is related to chemoresistance in various cancer cells, we investigated the function of FOXO1 in CDDP resistance in human gastric cancer cells. Methods Human gastric cancer cell lines MKN45 and SNU-601 were used. FOXO1 activation was modulated by transfection of FOXO1 AAA mutant gene or FOXO1 shRNA. The effects of FOXO1 on cell growth and CDDP cytotoxicity were assessed by crystal violet assay. Protein expressions of FOXO1, p110a, pAkt, and Akt were analyzed by Western blotting, and FOXO1 mRNA expression was evaluated by semiquantitative reverse transcription-polymerase chain reaction. FOXO1 activity was determined by luciferase reporter assay, and cell apoptosis was assessed by DAPI staining and Western blotting for PARP cleavage. Results Cisplatin treatment induced FOXO1 expression and activation in both gastric cancer cell lines. FOXO1 overexpression increased the CDDP resistance without changes in cell growth, whereas FOXO1 silencing enhanced CDDP cytotoxicity along with apoptotic characteristics. Both constitutive and CDDP-induced FOXO1 activations were accompanied by an increase in p110a and pAkt expression. Furthermore, Akt inhibition by LY294002 treatment restored the CDDP cytotoxicity that was suppressed by FOXO1 overexpression. Conclusion FOXO1 inhibits CDDP-induced apoptosis in gastric cancer cells via activating PI3K/Akt pathway. Thus, FOXO1 may be an useful pharmacological indicator to predict CDDP efficacy in gastric cancer treatment.
Introduction
Gastric cancer is one of the most common cancers and a major cause of cancer-related death worldwide [1] . However, the cure rate of this disease is limited because of the ineffectiveness of chemotherapy and radiotherapy. Thus, evaluation of the chemosensitivity of gastric cancer cells to anti-cancer agents based on phenotypic difference of individual cell lines will provide more information for choosing the correct drugs for gastric cancer patients.
Cisplatin (cis-diamminedichloroplatinium (II), CDDP) is a front-line chemotherapeutic agent in the treatment of advanced gastric cancer [2] . However, almost all cancer cells acquire resistance to CDDP, which reduces its efficacy [3] . Thus, molecules and factors that are capable of predicting responses of gastric cancer patients to CDDP treatment require investigation.
The FOXO (Forkhead box, class O) is a subfamily of forkhead transcription factor and consists of FOXO1, FOXO3A, FOXO4, and FOXO6 [4] . FOXO transcription factors are involved in diverse intracellular signaling pathways and regulate cell-cycle arrest, apoptosis, DNA damage repair, and detoxification of reactive oxygen species by regulating specific gene settings [5, 6] . The FOXO signaling is regulated by interactions with other intracellular proteins as well as their posttranslational modifications such as phosphorylation [7] .
The function of FOXO1 in chemoresistance in cancer cells has been evaluated in in vitro studies [8] [9] [10] . FOXO1 increased doxorubicin resistance in breast cancer cells [8] and paclitaxel resistance in ovarian cancer cells [9] , whereas it decreased CDDP resistance in ovarian cancer cells [10] . Thus, the effect of FOXO1 on the chemoresistance of cancer cells may differ according to the drug and cell type investigated.
The serine-threonine kinase Akt/protein kinase B is a well-known cell survival signal that contributes chemoresistance in a variety of cancer cells [11] . A recent study [12] has demonstrated that Akt overexpression decreases the chemosensitivity of gastric cancer cells to CDDP in vitro and in vivo. Although FOXO1 is a downstream target of Akt in human cancers [13] , association between FOXO1 activation and chemoresistance in gastric cancer cells has not been reported.
In the present study, we investigated whether FOXO1 activation is related to CDDP resistance in gastric cancer cell lines. For this, we modulated FOXO1 activation by transfection of FOXO1 AAA mutant gene or FOXO1 shRNA. In addition, we examined the association between FOXO1 and phosphoinositide-3-kinase (PI3K)/Akt pathway in relation to CDDP resistance in gastric cancer cells.
Materials and methods

Chemicals
Cisplatin was purchased from Sigma (St. Louis, MO, USA), and LY294002 was purchased from Cell Signaling Technology (Beverly, MA, USA).
Cell lines and cultures
Human gastric cancer cell lines MKN45 and SNU-601 were purchased from the Korean Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum (FBS), 2 mg/ml sodium bicarbonate, 100 U/ml penicillin, and 100 lg/ml streptomycin (Life Technologies) at 37°C in a humidified 95 % air and 5 % CO 2 atmosphere.
Stable transfection with a plasmid expressing FOXO1 AAA mutant gene An expression vector, pcDNA3, with a human FOXO1 AAA mutant gene (Addgene plasmid 13508), was purchased from Addgene (Cambridge, MA, USA). This vector encodes a constitutively active FOXO1 containing a threonine-to-alanine substitution at residue 24 and serine-toalanine substitution at 256 and 319. This construct (1 lg) or empty pcDNA3 vector (1 lg) was transfected into 3 9 10 5 cells/well in six-well plates using LipofectAMINE Plus (Life Technologies) according to the manufacturer's instructions. Pooled G418 (3 lg/ml)-resistant cells were used for further analysis.
Lentivirus-mediated shRNA silencing of FOXO1 FOXO1 shRNA lentiviral particles and nontargeting shRNA control particles were purchased from Sigma. The sequence of the shRNA targeting FOXO1 used in the present study is the following: CCGGGCCTGTTATC AATCTGCTAAACTCGAGTTTAGCAGATTGATAACA GGCTTTTTG. The nontargeting shRNA control particles contain four base-pair mismatches within the short hairpin sequence to any known human or mouse gene. The viral infection was performed by incubating gastric cancer cells in the culture medium containing lentiviral particles for 12 h in the presence of 5 lg/ml Polybrene (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Pooled puromycin (2 lg/ml)-resistant cells were harvested and stored for further analysis. 
Semiquantitative reverse transcription-polymerase chain reaction (SQ RT-PCR)
Semiquantitative reverse transcription-polymerase chain reaction was performed to determine the transcript level of FOXO1 in human gastric cancer cells, and the amplification of b-actin transcripts was used as the control to normalize the transcript levels of FOXO1. Total RNAs were isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), and reverse transcription was performed to synthesize cDNAs in a 20-ll reaction mixture containing each gene-specific primer, 1 lg RNA, 29 reaction buffer, 0.4 ll Taq polymerase, and 1.2 mM MgCl 2 . The cDNAs of FOXO1 transcripts were all amplified for 25 cycles (30 s at 94°C, 1 min at 57°C, and 1 min at 72°C), and the cDNAs of b-actin transcripts were amplified for 18 cycles (94°C for 30 s, 52°C for 30 s, and 70°C for 30 s). The PCR cycling numbers had been optimized to avoid the amplification saturation. Then, 5 ll of RT-PCR product was separated on 1 % agarose gels, which were subsequently stained with ethidium bromide. Primer sequences were 5 0 -GCAGATCTACGAGTGGATGGTC-3 0 and 5 0 -A AACTGTGATCCAGGGCTGTC-3 0 for FOXO1, and 5 0 -A CACCTTCTACAATGAGCTG-3 0 and 5 0 -CATGATGG AGTTGAAGGTAG-3 0 for b-actin.
Luciferase reporter assay
Gastric cancer cells were seeded in 24-well plates at a density of 3 9 10 4 cells/well and were transiently cotransfected with 0.4 lg forkhead responsive element (FHRE)-luciferase reporter plasmid (reporter construct in which a small region of the Fas ligand promoter containing the three FHREs, Addgene plasmid 1789) and 0.4 lg bgalactosidase vector, an internal control, using Lipofectamine Plus (Life Technologies). Twenty-four hours after transfection, assays for luciferase and b-galactosidase were carried out using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Luciferase activity was measured on an AutoLumat LB 9505c luminometer (Berthold Analytical Instruments, Nashua, Germany) and was normalized by b-galactosidase activity. Luciferase activity in control cells was arbitrarily set to 1.
Cell proliferation and cytotoxicity assay Cells were seeded onto 24-well plates, at a density of 1 9 10 4 cells/well for cell growth, and cultured for 4 days. To study the effects of CDDP on cell viability, 3 9 10 4 cells/well were seeded onto 24-well plates. After 24 h, cells were treated with various concentrations of CDDP dissolved in 0.02 % dimethyl sulfoxide (DMSO) (range, 0.1-3 lg/ml) for 24 h. For PI3K/Akt inhibition, cells were treated with 20 lM LY294002. Control columns contained cells without drug and blank columns contained medium alone. Cell numbers were measured indirectly using the method reported by Kim et al. [14] . Briefly, attached cells were stained with 0.2 % crystal violet aqueous solution in 20 % methanol for 10 min, dissolved in 10 % SDS, transferred into 96-well plates, and the absorbance was measured at 570 nm using an enzyme-linked immunosorbent assay reader (Bio-Rad, Hercules, CA, USA). Absorbance values were normalized to the values obtained for the medium control group cells to determine the survival percentage.
Apoptosis was evaluated by DAPI staining as described previously [15] . Briefly, cells were fixed with 4 % paraformaldehyde for 30 min, washed three times with phosphatebuffered saline (PBS), and stained with DAPI (1 lg/ml) in the dark for 30 min and then examined under a fluorescence microscope. Cells were considered apoptotic if their nuclei were condensed or fragmented.
Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA), and differences were considered significant at P \ 0.05 in the Newman-Keuls multiple-comparisons test. GraphPad Prism 4.00 for Windows Vista (GraphPad Software, San Diego, CA, USA) was used to conduct the analysis.
Results
CDDP induces FOXO1 expression and activation in gastric cancer cells
We investigated the correlation between FOXO1 and chemoresistance to CDDP in gastric cancer cells. First, we FOXO1 and cisplatin resistance 425 treated parent gastric cancer cell lines MKN45 and SNU-601 with CDDP (3 lg/ml) for 24 h and found that the expressions of FOXO1 protein (Fig. 1a, top) and mRNA (Fig. 1a, bottom) were increased in both cell lines. The induction of FOXO1 activation was confirmed by a luciferase reporter assay with a FHRE luciferase plasmid (Fig. 1b) . These results indicate that CDDP activates FOXO1 in gastric cancer cells.
FOXO1 activation in gastric cancer cell lines confers resistance to CDDP-induced cytotoxicity
To clarify the role of FOXO1 in CDDP resistance in gastric cancer cells, we modulated the FOXO1 activation. As Gao et al. [10] reported that FOXO1 increased CDDP cytotoxicity of ovarian cancer cells, we transfected the FOXO1 AAA mutant gene, a constitutively active FOXO1 mutant, into gastric cancer cell lines MKN45 and SNU-601 [16] . Western blotting (Fig. 2a) and luciferase reporter assay (Fig. 2b) showed that FOXO1 expression and transcriptional activity were increased, respectively, in stably FOXO1 AAA expressing cells compared with vector control cells. Under normal culture conditions, FOXO1
overexpression had no effect on the cell growth of the gastric cancer cells (Fig. 2c) . By contrast, treatment with CDDP (0-3 lg/ml) for 24 h showed that FOXO1 overexpression increased resistance to CDDP (Fig. 2d) .
To further confirm our results, as already mentioned, gene silencing by RNA interference was used. FOXO1 expression (Fig. 3a) and activity (Fig. 3b) were suppressed by FOXO1 shRNA expression in both cell lines. There was no difference in growth rates between gastric cancer cells (Fig. 3c) . To confirm the effect of FOXO1 on resistance to CDDP, cells were treated with CDDP (0-1 lg/ml) for 24 h. Figure 3d shows that FOXO1 silencing increased CDDP cytotoxicity in gastric cancer cells compared to cells without FOXO1 silencing. To examine whether CDDPinduced cell death occurs via apoptosis, we performed Western blotting for PARP (a caspase substrate) cleavage. After CDDP (1 lg/ml) treatment for 24 h, cleaved PARP was increased in FOXO1 shRNA-expressing cells compared to control shRNA-expressing cells (Fig. 3e) . The presence of apoptosis was confirmed by DAPI staining, which showed more frequent peripheral chromatin condensation and nuclear fragmentation in FOXO1 shRNA cells than in control shRNA cells (Fig. 3f) . Taken together, these results indicate that FOXO1 protects gastric cancer cells to CDDP-induced cell death.
FOXO1 activation enhances PI3K/Akt activity
Recently, it has been reported that Akt overexpression decreases the chemosensitivity of gastric cancer cells to CDDP in vitro and in vivo [12] . Although FOXO1 is a well-known downstream substrate of Akt, FOXO1 was shown to enhance Akt phosphorylation in hepatocytes [17] . directly increased and decreased the expressions of p110a, the class I PI3K catalytic subunit, and pAkt, the active form of Akt, respectively (Fig. 4a) . In addition, CDDP-induced FOXO1 expression was accompanied by the expressions of p110a and pAkt (Fig. 4b ).
FOXO1 enhances CDDP resistance through PI3K/Akt pathway
To confirm whether the positive correlation between FOXO1 and CDDP resistance is mediated by Akt, we increased constitutive FOXO1 activation by transfection of FOXO1 AAA mutant gene into gastric cancer cell lines and then assessed the effects of 20 lM LY294002 treatment on CDDP-induced cytotoxicity. Western blotting showed that gastric cancer cells expressing FOXO1 AAA mutant gene showed higher pAkt expression than vector control cells, but LY294002 treatment for 24 h effectively blocked pAkt expression (Fig. 5a ). Cytotoxicity assay showed that FOXO1 AAA cells treated with LY294002 showed higher CDDP cytotoxicity, which suggests that Akt inhibition enables gastric cancer cells to resume the CDDP sensitivity suppressed by FOXO1 overexpression (Fig. 5b) .
Discussion
Because FOXO transcription factors are critical mediators of apoptosis in cytotoxicity-inducing drugs, their involvement in the development of drug resistance is an important issue in cancer therapy [6] . However, FOXO proteins possess diverse functions, which partly seemed conflicting, according to drug and cell type [5] . To the best of our knowledge, this is the first study to demonstrate the correlation between FOXO1 and chemoresistance in gastric cancer cells. We have previously shown that phosphorylated FOXO1 is overexpressed in gastric cancer specimens and that FOXO1 inactivation is related to better prognosis of gastric cancer patients [18] . Although FOXO proteins, especially FOXO1 and FOXO3, have been reported to be related to chemoresistance in various cancer cells [8] [9] [10] [19] [20] [21] , their involvement in chemoresistance of gastric cancer cells has not been reported. In the present study, we used two gastric cancer cell lines, MKN45 and SNU-601, with constitutive FOXO1 expression and found that CDDP treatment increased the levels of FOXO1 protein expression and activation. Because CDDP treatment also increased FOXO1 mRNA expression, CDDP-induced FOXO1 transcription seems to contribute to the accumulation of FOXO1 protein. These results suggest that FOXO1 might impart the phenotype of CDDP resistance in gastric cancer cells.
Gene modulation is a powerful method for analyzing gene function [22] . Here, we confirmed the function of FOXO1 on CDDP resistance in two gastric cancer cell lines by modulation of FOXO1 activation using two different approaches (expression of FOXO1 AAA mutant gene and FOXO1 shRNA). We found that constitutive activation of FOXO1 increased the CDDP resistance in gastric cancer cells, whereas cell growth was not affected. In contrast, FOXO1 silencing with shRNA-enhanced CDDP-induced cytotoxicity accompanied by apoptotic characteristics, including cleaved PARP expression and fragmented nuclei. Taken together, these observations clearly demonstrated that FOXO1 is protective to CDDPinduced cytotoxicity in gastric cancer cells. Thus, blockage of FOXO1 could be an effective approach to improve the anti-cancer efficacy of CDDP in gastric cancer patients.
It is generally accepted that Akt is a critical survival signal, which is involved in cancer development and progression and chemoresistance [11] . Although cancer cells acquire resistance to anti-cancer agents through Akt, either constitutive or induced by anti-cancer drugs, the molecular mechanisms underlying anti-cancer drug-induced Akt activation are not well elucidated. In gastric cancer, we have observed that pAkt is expressed in 78 % of gastric cancer specimens [23] . As a recent study showed that Akt overexpression decreases the chemosensitivity of gastric cancer cells to CDDP in vitro and in vivo [12] , we investigated whether Akt is related to the FOXO1 regulation of CDDP cytotoxicity in gastric cancer cells. In the present study, constitutive activation and silencing of Our results agree with those of Hui et al. [19] , which showed FOXO3-induced PI3K/Akt activation in response to doxorubicin treatment of chronic myelogenous leukemia cells. However, our observations contrast with those of Gao et al. [10] , which demonstrated that FOXO1 enhanced CDDP cytotoxicity in ovarian cancer cells. These discrepancies may, at least in part, be explained by a previous suggestion by Paik et al. [24] that FOXO-regulated genes are different significantly between cell types. Indeed, FOXO1 induced multidrug resistance expression in breast cancer cells [25] , whereas it upregulated the expressions of proapoptotic Bim and TRADD in ovarian cancer cells [10] .
In conclusion, our results suggest that concurrent blocking of FOXO1 and Akt pathways is an effective strategy for improving the anti-cancer efficacy of CDDP. Thus, our results provide important clues for the efficient CDDP-design for future studies on gastric cancer treatment. Studies on the association between FOXO1 and chemosensitivity in gastric cancer cells using human gastric cancer specimens with animal models are warranted to verify the usefulness of this strategy.
